Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.96+0.00 (0.00%)
Close on Nov 18, 2026Market cap $1.31BP/E –Yield –
Novavax net income
Net income is the profit left for shareholders after every expense, interest and tax.
Novavax's net income for the twelve months ending Jun 30, 2026 was -$247.73M, down 158.6% year over year. For fiscal 2025 it was $440.30M. The highest annual figure on record is $440.30M in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $440.30M | – |
| FY2024 | Dec 31, 2024 | -$187.50M | – |
| FY2023 | Dec 31, 2023 | -$545.06M | – |
| FY2022 | Dec 31, 2022 | -$657.94M | – |
| FY2021 | Dec 31, 2021 | -$1.74B | – |
| FY2020 | Dec 31, 2020 | -$418.26M | – |
| FY2019 | Dec 31, 2019 | -$132.69M | – |
| FY2018 | Dec 31, 2018 | -$184.75M | – |
| FY2017 | Dec 31, 2017 | -$183.77M | – |
| FY2016 | Dec 31, 2016 | -$279.97M | – |
| FY2015 | Dec 31, 2015 | -$156.94M | – |
| FY2014 | Dec 31, 2014 | -$82.95M | – |
| FY2013 | Dec 31, 2013 | -$51.98M | – |
| FY2012 | Dec 31, 2012 | -$28.51M | – |
| FY2011 | Dec 31, 2011 | -$19.36M | – |
| FY2010 | Dec 31, 2010 | -$35.71M | – |
| FY2009 | Dec 31, 2009 | -$40.35M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$53.39M | -150.1% |
| Q1 FY2026 | Mar 31, 2026 | -$9.49M | -101.8% |
| Q4 FY2025 | Dec 31, 2025 | $17.53M | – |
| Q3 FY2025 | Sep 30, 2025 | -$202.38M | – |
| Q2 FY2025 | Jun 30, 2025 | $106.51M | -34.4% |
| Q1 FY2025 | Mar 31, 2025 | $518.65M | – |
| Q4 FY2024 | Dec 31, 2024 | -$81.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$121.30M | – |
| Q2 FY2024 | Jun 30, 2024 | $162.38M | +179.9% |
| Q1 FY2024 | Mar 31, 2024 | -$147.55M | – |
| Q4 FY2023 | Dec 31, 2023 | -$178.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$130.78M | – |
| Q2 FY2023 | Jun 30, 2023 | $58.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$293.91M | -244.5% |
| Q4 FY2022 | Dec 31, 2022 | -$182.25M | – |
| Q3 FY2022 | Sep 30, 2022 | -$168.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -$510.49M | – |
| Q1 FY2022 | Mar 31, 2022 | $203.41M | – |
| Q4 FY2021 | Dec 31, 2021 | -$846.28M | – |
| Q3 FY2021 | Sep 30, 2021 | -$322.43M | – |
| Q2 FY2021 | Jun 30, 2021 | -$352.32M | – |
| Q1 FY2021 | Mar 31, 2021 | -$222.72M | – |
| Q4 FY2020 | Dec 31, 2020 | -$177.56M | – |
| Q3 FY2020 | Sep 30, 2020 | -$197.31M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.52M | – |
| Q1 FY2020 | Mar 31, 2020 | -$25.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$31.83M | – |
| Q3 FY2019 | Sep 30, 2019 | -$18.04M | – |
| Q2 FY2019 | Jun 30, 2019 | -$39.60M | – |
| Q1 FY2019 | Mar 31, 2019 | -$43.22M | – |
| Q4 FY2018 | Dec 31, 2018 | -$49.33M | – |
| Q3 FY2018 | Sep 30, 2018 | -$44.57M | – |
| Q2 FY2018 | Jun 30, 2018 | -$44.49M | – |
| Q1 FY2018 | Mar 31, 2018 | -$46.35M | – |
| Q4 FY2017 | Dec 31, 2017 | -$50.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -$44.61M | – |
| Q2 FY2017 | Jun 30, 2017 | -$44.47M | – |
| Q1 FY2017 | Mar 31, 2017 | -$43.85M | – |
| Q4 FY2016 | Dec 31, 2016 | -$57.11M | – |
| Q3 FY2016 | Sep 30, 2016 | -$66.25M | – |
See a number that looks wrong?